239 related articles for article (PubMed ID: 28040425)
1. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis.
Baldini C; Escande A; Bouché O; El Hajbi F; Volet J; Bourgeois V; Renaut Vantroys T; Ploquin A; Desauw C; Hebbar M
Pancreatology; 2017; 17(1):146-149. PubMed ID: 28040425
[TBL] [Abstract][Full Text] [Related]
2. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
3. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
5. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
6. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
[TBL] [Abstract][Full Text] [Related]
7. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
10. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
[TBL] [Abstract][Full Text] [Related]
11. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
12. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Marthey L; Sa-Cunha A; Blanc JF; Gauthier M; Cueff A; Francois E; Trouilloud I; Malka D; Bachet JB; Coriat R; Terrebonne E; De La Fouchardière C; Manfredi S; Solub D; Lécaille C; Thirot Bidault A; Carbonnel F; Taieb J
Ann Surg Oncol; 2015 Jan; 22(1):295-301. PubMed ID: 25037971
[TBL] [Abstract][Full Text] [Related]
14. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
[TBL] [Abstract][Full Text] [Related]
15. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
Ulusakarya A; Teyar N; Karaboué A; Haydar M; Krimi S; Biondani P; Gumus Y; Chebib A; Almohamad W; Morère JF
Medicine (Baltimore); 2019 Apr; 98(16):e15341. PubMed ID: 31008993
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
[TBL] [Abstract][Full Text] [Related]
17. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
[TBL] [Abstract][Full Text] [Related]
18. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
[TBL] [Abstract][Full Text] [Related]
19. Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.
Schlick K; Magnes T; Ratzinger L; Jaud B; Weiss L; Melchardt T; Greil R; Egle A
PLoS One; 2018; 13(11):e0206688. PubMed ID: 30412592
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
